| Jodi R Lutz, NP | |
|
1650 Washington Ave, Alton, IL 62002-3931 | |
| (314) 687-2735 | |
| Not Available |
| Full Name | Jodi R Lutz |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 1650 Washington Ave, Alton, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063996130 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associated Physicians Group Ltd | 5698674802 | 16 |
News Archive
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.
Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.
A research team led by Associate Professor Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL) has developed a sensitive and accurate way of identifying gene copy number variations (CNVs).
People who suffer cardiac arrests and then receive coronary angiography are twice as likely to survive without significant brain damage compared with those who don't have the procedure, according to a study by University of Pittsburgh School of Medicine researchers.
› Verified 4 days ago
| Entity Name | Associated Physicians Group Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811940893 PECOS PAC ID: 5698674802 Enrollment ID: O20040107000499 |
News Archive
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.
Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.
A research team led by Associate Professor Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL) has developed a sensitive and accurate way of identifying gene copy number variations (CNVs).
People who suffer cardiac arrests and then receive coronary angiography are twice as likely to survive without significant brain damage compared with those who don't have the procedure, according to a study by University of Pittsburgh School of Medicine researchers.
› Verified 4 days ago
| Entity Name | Interventional Pain Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336461771 PECOS PAC ID: 1153451919 Enrollment ID: O20240122000604 |
News Archive
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.
Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.
A research team led by Associate Professor Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL) has developed a sensitive and accurate way of identifying gene copy number variations (CNVs).
People who suffer cardiac arrests and then receive coronary angiography are twice as likely to survive without significant brain damage compared with those who don't have the procedure, according to a study by University of Pittsburgh School of Medicine researchers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jodi R Lutz, NP Po Box 955534, Saint Louis, MO 63195-5534 Ph: () - | Jodi R Lutz, NP 1650 Washington Ave, Alton, IL 62002-3931 Ph: (314) 687-2735 |
News Archive
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.
Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.
A research team led by Associate Professor Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL) has developed a sensitive and accurate way of identifying gene copy number variations (CNVs).
People who suffer cardiac arrests and then receive coronary angiography are twice as likely to survive without significant brain damage compared with those who don't have the procedure, according to a study by University of Pittsburgh School of Medicine researchers.
› Verified 4 days ago
Mrs. Misty D Biciocchi, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4 Memorial Dr, Ste 134, Alton, IL 62002 Phone: 618-607-1340 Fax: 618-622-9724 | |
Lee A Tardino, MSN ANP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4 Memorial Dr Ste 210, Alton, IL 62002 Phone: 618-463-5905 Fax: 618-463-5935 | |
Lisa K James, ANP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4 Memorial Dr Ste 230, Alton, IL 62002 Phone: 618-433-6170 | |
Laura L Brandenburg, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4 Memorial Dr, Ste 230b, Alton, IL 62002 Phone: 618-463-7777 Fax: 618-463-7767 | |
Kelsey M Beard, FNP-BC, DNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4 Memorial Dr Ste 210, Alton, IL 62002 Phone: 618-463-5905 Fax: 618-463-5035 | |
Anissa Fay Washington, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Dr, Alton, IL 62002 Phone: 618-463-7300 |